Orai1α and Orai1β more potently promote NFAT activation and transcription than Orai2 and Orai3
This study demonstrates that Orai1α and Orai1β isoforms are significantly more potent than Orai2 and Orai3 in driving NFAT activation and transcription by supporting greater store-operated calcium entry (SOCE), a finding further supported by evidence that the loss of Orai1α in humans does not cause CRAC channelopathy and may even enhance SOCE and NFAT responses.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside nearly every cell of the human body, a silent, constant conversation takes place. It is a dialogue written in calcium, a mineral that flows in and out of cells to act as a universal messenger. When a cell needs to react to its environment—whether an immune cell fighting an infection or a muscle cell preparing to move—it opens tiny gates in its outer wall. These gates, known as CRAC channels, allow calcium to rush in from the outside world. This sudden influx of calcium acts like a switch, turning on the machinery inside the cell that tells it what to do next. One of the most important things this calcium signal does is travel to the cell's command center, the nucleus, to wake up specific genes. These genes then produce proteins that allow the cell to grow, divide, or release chemicals to fight disease. Without this precise flow of calcium, our immune system would fail to protect us, and our bodies would struggle to respond to the world around them.
For decades, scientists have known that the cell uses a family of proteins called Orai to build these calcium gates. There are three main types of Orai proteins, and they work together to control the flow. However, one of these proteins, Orai1, is special because it comes in two slightly different versions, like two editions of the same book. One version is longer and found only in mammals, while the other is shorter and has been around since the earliest days of vertebrate life. A long-standing question in biology has been whether these two versions of the same protein do the exact same job, or if they send different messages to the cell's nucleus. If they send different messages, it could mean that the length of the protein matters for how our immune system functions.
A team of researchers set out to answer this question by looking at how these different versions of the Orai protein control the activation of a master gene regulator called NFAT. Think of NFAT as a foreman who waits in the main office of the cell. When calcium flows in through the Orai gates, it signals the foreman to leave his post and enter the nucleus to start construction on new genes. The researchers wanted to know if the long version of Orai1 and the short version were equally good at calling this foreman to work, or if one was more powerful than the other. To find out, they used a very careful approach. Instead of flooding cells with too much protein, which can distort the results, they engineered cells to produce just the right amount of each Orai version, mimicking how they naturally exist in the body. They tested these cells in the lab and also looked at human genetic data to see what happens in real people.
The results were clear and surprising. The researchers found that both versions of the Orai1 protein are fully capable of opening the calcium gates and calling the NFAT foreman to the nucleus. In fact, the shorter, older version of the protein was actually slightly more effective at generating a strong calcium signal than the longer, mammal-specific version. This suggests that the extra length of the mammal-only version does not give it a special superpower; rather, the shorter version is the original, highly efficient tool that evolution has kept for hundreds of millions of years. The strength of the signal sent to the nucleus depended mostly on how much calcium flowed through the gate, not on which specific version of the protein built the gate.
To confirm that this held true in living organisms, the researchers turned to primary immune cells, specifically T cells, which are the soldiers of the immune system. They took T cells from mice that were missing their own Orai1 protein and replaced them with either the long or the short version. Both versions successfully restored the cells' ability to sense calcium, move the NFAT foreman to the nucleus, and produce the chemical signals needed to fight infection. When the researchers looked at the thousands of genes turned on by these cells, they found that both versions of the protein triggered nearly identical genetic programs. The cells behaved almost exactly the same, proving that the two versions are interchangeable in their ability to drive immune responses.
The study also looked at real human data to see if people who naturally lack the long version of the protein suffer from any immune diseases. Scientists have long known that people with broken Orai1 genes often get severe, life-threatening infections because their immune cells cannot activate properly. However, the researchers found that individuals who have a genetic mutation that removes only the long version of the protein, leaving the short version intact, do not get sick. These people have healthy immune systems. In fact, their immune cells showed an even stronger calcium response than people with both versions. This confirms that the short version of the protein is sufficient to keep the immune system running smoothly and that the long version is not essential for human health.
By combining lab experiments with human genetic analysis, the researchers demonstrated that the two versions of the Orai1 protein are functionally equivalent in their ability to control gene activation. The cell does not need the longer, mammal-specific version to survive or fight disease. The shorter, ancient version is fully capable of doing the job, and in some cases, it does it even better. This finding simplifies our understanding of how our immune system works, showing that the core machinery is robust and that the body can rely on the older, shorter version of the protein to protect us just as effectively as the newer, longer one.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.